Details of issuance or disposal
Report on the Exercise Status of the 16th Series of Stock Acquisition Rights Issued through a Third-Party Allotment (with an Option to Revise the Exercise Price)
New shares: 104,300 shares (104,300 shares during the relevant month)
Amount of funds raised: ¥497,746,000; estimated net proceeds: Not disclosed
Exercise ratio subject to exercise restrictions: 3.0% (204,300 shares delivered across all series / 6,884,900 listed shares as of the payment date for the issuance); exercise ratio for this exercise of the 16th Series of Stock Acquisition Rights: 16.0% (1,043 units / 6,515 units issued)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Report on the Exercise Status of the 16th Series of Stock Acquisition Rights Issued through a Third-Party Allotment (with an Option to Revise the Exercise Price) |
| Number of shares to be issued or disposed of | New shares: 104,300 shares (104,300 shares during the relevant month) |
| Amount of funds to be raised | Amount of funds raised: ¥497,746,000; estimated net proceeds: Not disclosed |
| Intended allottee | Cantor Fitzgerald Europe (allottee at the time of issuance) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 3.0% (204,300 shares delivered across all series / 6,884,900 listed shares as of the payment date for the issuance); exercise ratio for this exercise of the 16th Series of Stock Acquisition Rights: 16.0% (1,043 units / 6,515 units issued) |
| Total number of issued shares | 8,912,700 shares (as of 30 April 2026) → Not disclosed |
| Exercise price | Exercise price: ¥764; details of the adjustment provisions and adjustment floor: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 6,515 units; units exercised: 6,515 units; units remaining unexercised: 0 units |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Timing 26 December 2025 / Type Issuance of the 16th Series of Stock Acquisition Rights (with an Option to Revise the Exercise Price) / Amount Not disclosed |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the bulk exercise of these Stock Acquisition Rights completed all exercises.